trivalent influenza vaccine-Beijing Chaoyang District Centre for Disease Control and Prevention-influenza

This trivalent influenza vaccine refers to a biological product evaluated in clinical trials sponsored by the Beijing Chaoyang District Centre for Disease Control and Prevention for the prevention of seasonal influenza. Typically formulated as an inactivated split-virion or subunit vaccine, it contains hemagglutinin antigens from three distinct influenza virus strains: two influenza A subtypes (H1N1 and H3N2) and one influenza B lineage. In clinical research, such as Phase 3 studies (e.g., NCT03266185), this vaccine serves as an active comparator to assess the relative safety and immunogenicity of newer quadrivalent formulations. The vaccine works by inducing active immunity through the production of neutralizing antibodies against the viral hemagglutinin, thereby protecting the recipient from infection and reducing the severity of influenza-related disease.

Other names

trivalent influenza vaccinetrivalent influenza virus vaccinecommercially available trivalent influenza vaccine